We are studying whether observing patients after surgery is as effective as continuing pembrolizumab treatment for those who responded well to initial therapy. This trial also looks at safety, quality of life, and fertility impacts.
Health conditions and diseases that the clinical trial is designed to study and treat.
Early Triple-Negative Breast Cancer (TNBC) is a type of breast cancer that does not have any of the three common receptors known to fuel most breast cancer growth. Patients achieving a pathologic complete response (pCR) after neoadjuvant chemotherapy and pembrolizumab show no signs of cancer in tissue samples after treatment.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
